Erschienen in:
01.08.2012 | SHORT REPORT
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma
Erschienen in:
Investigational New Drugs
|
Ausgabe 4/2012
Einloggen, um Zugang zu erhalten
Excerpt
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer-related death [
1]. More than 75% of cases occur in the Asian-Pacific region, largely in association with chronic hepatitis B virus (HBV) infection, and 360,000 patients in Eastern Asia die from this disease each year [
1]. Diagnosed at early stages, it is potentially curable by surgery and by locoregional procedures. However, disease that is diagnosed at an advanced stage or continues to progress after locoregional therapy has a dismal prognosis because of underlying liver cirrhosis and lack of effective alternative treatments. …